Student and Faculty Publications
Publication Date
8-2-2024
Journal
Nature Communications
Abstract
Muscle invasive bladder cancers (BCs) can be divided into 2 major subgroups-basal/squamous (BASQ) tumors and luminal tumors. Since Pparg has low or undetectable expression in BASQ tumors, we tested the effects of rosiglitazone, Pparg agonist, in a mouse model of BASQ BC. We find that rosiglitazone reduces proliferation while treatment with rosiglitazone plus trametinib, a MEK inhibitor, induces apoptosis and reduces tumor volume by 91% after 1 month. Rosiglitazone and trametinib also induce a shift from BASQ to luminal differentiation in tumors, which our analysis suggests is mediated by retinoid signaling, a pathway known to drive the luminal differentiation program. Our data suggest that rosiglitazone, trametinib, and retinoids, which are all FDA approved, may be clinically active in BASQ tumors in patients.
Keywords
Animals, Urinary Bladder Neoplasms, Pyridones, Pyrimidinones, Rosiglitazone, Mice, Disease Models, Animal, Apoptosis, Humans, Cell Proliferation, Cell Line, Tumor, Antineoplastic Agents, Neoplasm Invasiveness, Female, PPAR gamma, Thiazolidinediones, Cell Differentiation, Signal Transduction, Retinoids
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons
Comments
Supplementary Materials
Data Availability Statement
PMID: 39095358